Embryo Genetic Analysis
Before an embryo is transferred, genetic testing can identify the healthiest candidates — reducing miscarriage risk, improving implantation rates, and offering peace of mind about inherited conditions.
Preimplantation Genetic Testing (PGT) is a laboratory procedure performed on embryos created through IVF before transfer to the uterus. A small number of cells are biopsied from the blastocyst and sent to a genetics laboratory for analysis.
PGT allows IRFC's physicians to select the embryo most likely to result in a healthy, ongoing pregnancy — and to avoid transferring embryos with chromosomal or genetic abnormalities that would lead to failed implantation, miscarriage, or an affected child.
Why chromosomal errors matter
Chromosomal abnormalities are the most common cause of failed IVF implantation and early miscarriage. Their frequency increases significantly with maternal age:
Estimates based on published ART literature. Individual results vary.
Tests embryos for the correct number of chromosomes (46 total). Chromosomal errors (aneuploidy) are the leading cause of IVF failure and miscarriage — especially in women over 35. PGT-A identifies euploid (chromosomally normal) embryos for transfer.
Best for: Advanced maternal age, recurrent pregnancy loss, repeated IVF failure
Screens embryos for specific single-gene disorders — such as cystic fibrosis, sickle cell disease, BRCA mutations, Huntington's disease, and hundreds of others — when one or both parents are known carriers.
Best for: Known carriers of a specific inherited condition
Identifies chromosomal structural changes (translocations, inversions) that can cause IVF failure or recurrent miscarriage, even when one parent is a balanced carrier with no apparent health impact.
Best for: Couples with a known chromosomal structural rearrangement
PGT significantly reduces the risk of specific chromosomal or genetic conditions — but it cannot screen for all possible abnormalities. It is an important risk-reduction tool, not an absolute guarantee. Your physician will discuss realistic expectations.
At the blastocyst stage (day 5–6), an embryologist uses a laser to remove a small number of trophectoderm cells (which become the placenta, not the baby). The embryo is then frozen while biopsy results are awaited. Studies confirm this process does not harm the embryo.
Biopsy results typically return within 10–14 days. Your physician will review results with you and recommend which embryos are best suited for transfer.
For appropriate candidates, yes — particularly women over 35, those with recurrent miscarriage, or those with prior IVF failures. By selecting chromosomally normal embryos, PGT-A reduces miscarriage risk and improves implantation rates per transfer.
Embryos with detected abnormalities are not transferred. Patients may choose to discard them, donate them to research, or in some cases, discuss options with genetic counselors and their physician.
PGT is a powerful tool for the right patients. Our physicians will help you determine whether it makes sense for your situation.